NeuroMetrix Past Earnings Performance

Past criteria checks 0/6

NeuroMetrix's earnings have been declining at an average annual rate of -17.9%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 11% per year.

Key information

-17.9%

Earnings growth rate

51.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-11.0%
Return on equity-48.0%
Net Margin-203.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

NeuroMetrix reports Q3 results

Oct 20

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11
We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19
Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Sep 09

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21
We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27
NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown

How NeuroMetrix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NURO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244-892
30 Jun 244-892
31 Mar 245-893
31 Dec 236-793
30 Sep 236-682
30 Jun 237-583
31 Mar 238-583
31 Dec 228-473
30 Sep 228-573
30 Jun 228-473
31 Mar 228-363
31 Dec 218-262
30 Sep 218-261
30 Jun 218-161
31 Mar 217-151
31 Dec 207-262
30 Sep 207-362
30 Jun 207-471
31 Mar 208-692
31 Dec 199-4112
30 Sep 1911-6133
30 Jun 1913-3144
31 Mar 19141154
31 Dec 18160155
30 Sep 18170164
30 Jun 1817-7174
31 Mar 1818-11173
31 Dec 1717-20173
30 Sep 1716-20173
30 Jun 1716-17173
31 Mar 1714-38164
31 Dec 1612-35164
30 Sep 1611-43164
30 Jun 1610-42154
31 Mar 168-23143
31 Dec 157-21133
30 Sep 156-13123
30 Jun 155-11113
31 Mar 155-12103
31 Dec 146-1183
30 Sep 146-1273
30 Jun 145-1173
31 Mar 145-872
31 Dec 135-983

Quality Earnings: NURO is currently unprofitable.

Growing Profit Margin: NURO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NURO is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.

Accelerating Growth: Unable to compare NURO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NURO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: NURO has a negative Return on Equity (-48.03%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:17
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeuroMetrix, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanDawson James Securities
Andrew FeinH.C. Wainwright & Co.
Anthony VendettiMaxim Group